iHeartMedia and Podimo Partner to Translate and Adapt Widely Popular Podcasts For Listeners Globally
iHeartMedia, the No. 1 audio company in America and the No. 1 podcast publisher globally, and European podcast platform Podimo today announced a strategic partnership to translate and adapt popular podcasts across the globe in different languages, introducing these podcasts to hundreds of millions of new listeners. The partnership will kick off with the widely popular true crime podcast “Forgotten: Women of Juárez” (Olvidadas: Muertes de Juárez) about femicides in Mexico’s most dangerous city in three languages: Spanish, German and Danish.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005440/en/
In one of 2020’s most intimate and shocking true crime podcasts, “Forgotten: Women of Juárez,” from iHeartMedia and Unusual Productions, hosts Mónica Ortiz Uribe and Oz Woloshyn investigate theories surrounding the disappearance of hundreds of young women along the Mexican border city of Juárez. Some are tragically found with symbols carved into their bodies or wrists bound with shoelaces -- is it a serial killer, organ traffickers, or a Satanic Cult? Executive produced by iHeartMedia and Unusual Productions, in partnership with Podimo, the adapted versions, starting with Spanish, will feature both existing content from the original podcast, plus exciting new elements including additional interviews with special hosts Rossana Fuentes-Berain and Sandra Romandía. The adapted podcast series will be released in early 2021 in 20 countries in Latin America, as well as in Spain and in the USA, followed by Podimo’s German and Danish markets at a later date. The original series will continue to be available on the iHeartRadio App and everywhere podcasts are available.
“This partnership is powerful. iHeartMedia’s understanding of great storytelling combined with Podimo’s ultra-local on-the-ground presence in Latin America and Spain will help us tell important stories like this to a local audience. We know that around 90% of all listening on Podimo is on local language podcasts, so translating good stories will help grow the audience for these stories tremendously,” said Eva Lægdsgaard, Chief of Strategic Relations at Podimo. “In the podcast business, everything begins and ends with great storytelling. But for great stories to have a great life, we need to drive large-scale listening numbers for our podcasters and publishers -- both locally and globally. This will help them monetize their content on a much bigger scale, and that is the very core of our business model.”
“We’re excited to partner with a podcast innovator like Podimo and use iHeartMedia’s unparalleled ability to introduce podcast listening at scale to bring some of the most fascinating local podcasts to millions of listeners worldwide,” said Conal Byrne, President of the iHeartPodcast Network. “Podcast listening continues to see tremendous growth as more and more listeners seek out layered storytelling, and we believe this venture with Podimo will help us to introduce great podcasts to new fans around the world.”
About Podimo:
Podimo is a European podcast platform that offers personal recommendations for users, while supporting creators through a new revenue share model. Currently live in Denmark, Germany, Spain, and across Latin America, the app features great podcasts from anywhere in the world via RSS feeds, and is free to download and listen with no login required. As a Premium member, you’ll unlock access to an additional 400+ Podimo produced and licensed shows that can’t be heard anywhere else, and your membership fee is shared directly with the podcast creators you listen to each month. https://podimo.com
About iHeartMedia
iHeartMedia (NASDAQ: IHRT) is the number one audio company in the United States, reaching nine out of 10 Americans every month – and with its quarter of a billion monthly listeners, has a greater reach than any other media company in the U.S. The company’s leadership position in audio extends across multiple platforms, including more than 850 live broadcast stations in over 160 markets nationwide; through its iHeartRadio digital service available across more than 250 platforms and 2,000 devices; through its influencers; social; branded iconic live music events; other digital products and newsletters; and podcasts as the #1 commercial podcast publisher. iHeartMedia also leads the audio industry in analytics, targeting and attribution for its marketing partners with its SmartAudio product, using data from its massive consumer base. Visit iHeartMedia.com for more company information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005440/en/
Contact information
To arrange an interview, please contact
Eva Lægdsgaard, Chief of Strategic Relations, Podimo
eva@podimo.com
+45 3150 9010
or
Angel Aristone, iHeartMedia
AngelAristone@iheartmedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom